HOME >> BIOLOGY >> NEWS
Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

  • First once-daily dosing results for the HIV protease inhibitor Agenerase :
    Clinical Importance: Development of once-daily HIV regimens represents a major advance toward simplified therapy for patients.

  • First phase II clinical results for amprenavir prodrug (VX-175):
    VX-175 could provide significant simplification of protease inhibitor-based therapy by potentially allowing dosing of just two or three pills, once or twice a day.

  • Meet with a Vertex medical director or clinical investigator to learn about advancements in Vertexs HIV product pipeline.

  • Learn how pharmacokinetic discoveries are enhancing dosage convenience and promoting patient adherence to therapy

February 4-8, 2001
Sheraton Hotel and Towers, Chicago, IL
Visit us at Posters #332 and 333 (Feb 6th)


'"/>

Contact: Renee Connolly
r.connolly@noonanrusso.com
212-696-4455 ext 227
Noonan/Russo Communications
6-Feb-2001


Page: 1

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study reports findings of combination therapy with DOXIL
9. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
10. Clinical trial shows timing of chemotherapy improves survival in breast cancer
11. Clinical services must catch up

Post Your Comments:
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... Conn. , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... new advertising campaign on CNBC television starting March 30 th ... will commence airing in New York ... Officer said: "We are excited about our new ad campaign ...
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
(Date:4/1/2015)... Mar. 30, 2015 Research and Markets ... of the "Blood Screening Market by Technology ... Immunoassay, Next Generation Sequencing, Western Blotting), Product (Instrument, ... Forecasts to 2019 " report to their ... expected to reach $2.55 billion by 2019 from ...
(Date:4/1/2015)... /CNW/ - Canada,s Research-Based Pharmaceutical Companies ... released report on Cost Drivers of Public Drug Plans in ... the report, the rates of change in drug costs have ... -0.8 percent in 2012/13 for a number of select public ... the costs of medicines without considering their overall impact on ...
(Date:4/1/2015)... Mar. 30, 2015 Research and Markets ... of the "Forensic Technologies and Services - ... offering. This report analyzes the US ... Million by the following Segments: Forensic Databases, Forensic ... Others. Annual estimates and forecasts are ...
(Date:4/1/2015)... 2015 Synthetic Biologics, Inc. (NYSE MKT: ... infections and diseases, with a focus on protecting ... the development of SYN-004, the Company,s candidate therapy ... within the gastrointestinal (GI) tract and maintain the ... prevention of C. difficile infection, antibiotic-associated ...
Breaking Biology Technology:Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 2Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 3Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 2Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 3Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 4Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 5Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 6Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 7Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 3Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 4
Cached News: